Table 2. Current dose escalation trials using IMRT for NSCLC.

Purpose	Title	ClinicalTrials.gov identifier	Status	Sponsor	Primary outcome
Using functional imaging to assess early response and dose escalate	Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT01507428	Ongoing, not recruiting	NCI	LRPFS; relative change in SUV peak from baseline to during-treatment PET/CT to LRPFS
	Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)	NCT02773238	Recruiting	UW	OS, compared to 60 Gy cohort of RTOG 0617
	Phase III Study of Individualized Adaptive Radiotherapy Based on PET/CT and 3DCRT/IMRT in Combination with Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT02790190	Recruiting	Shandong Cancer Hospital and Institute	OS
Using pre-treatment functional imaging to guide dose escalation	Dose Escalation by Boosting Radiation Dose Within the Primary Tumor on the Basis of a Pre-treatment FDG-PET-CT Scan in Stage IB, II and III NSCLC: A Randomized Phase II Trial	NCT01024829	Recruiting	NKI	1-year local progression-free survival rate
	A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy	NCT02788461	Recruiting	Lawson Health Research Institute	Reduction of locoregional failure rate
Personalized dose escalation based on doses to OARs	Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) - A Feasibility Study	NCT01836692	Ongoing, not recruiting	Heather Driscoll	Number of participants treated with isotoxic RT using IMRT and hyperfractionated accelerated RT
	INTENSE: A Phase I/II Study of Inhomogeneous Targeted Dose Escalation in Non-Small Cell Lung Cancer	NCT02764086	Ongoing, not recruiting	Cancer Trials Ireland	Proportion of grade ≥3 toxicities related to RT
	Phase I Dose Escalation Study of Accelerated Fractionation with Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury	NCT00921739	Ongoing, not recruiting	DU	Maximum tolerated dose of IMRT

IMRT, intensity-modulated radiation therapy; NSCLC, non-small cell lung cancer; NCI, National Cancer Institute; LRPFS, locoregional progression-free survival; SUV, standardized uptake value; PET/CT, positron emission tomography/computed tomography; UW, University of Washington; OS, overall survival; RTOG, Radiation Therapy Oncology Group; NKI, Netherlands Cancer Institute; OARs, organs at risk; RT, radiation therapy; DU, Duke University.